Publications by authors named "G E Cosgrove"
Article Synopsis
- Glioblastoma is described as immunologically "cold," making it resistant to solo immune-checkpoint inhibitors (ICI) like pembrolizumab, although neoadjuvant use may improve survival based on prior studies.
- A study involving 25 additional patients analyzed tumor tissue for gene signatures and found that neoadjuvant pembrolizumab led to decreased cancer proliferation genes and increased T-cell activity, indicating a specific response to this treatment.
- Despite observing these molecular changes, the study did not confirm an overall survival benefit from neoadjuvant pembrolizumab, suggesting that some patients may inherently resist ICI and may need additional therapies for effective treatment.
Article Synopsis
- Scholarship is becoming increasingly important in neurosurgery as grades turn to pass-fail, leading to a focus on metrics like research to distinguish applicants.
- The study analyzed characteristics of 228 US neurosurgery applicants and found that matched applicants published significantly more during residency compared to unmatched ones.
- Key factors linked to higher publication output include prior research experience, strong medical school grades, and the academic quality of the residency program, with program R25 status being particularly influential.
This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the in 2024. This study looked at a medicine called (beck-so-teh-grast) as a possible treatment for (i-dee-uh-pa-thick pul-muh-ner-ee fie-bro-sis; IPF). is an investigational medicine, which means that it is being studied and has not yet been approved by the US Food and Drug Administration (FDA), for people with IPF to take as a treatment.
View Article and Find Full Text PDFIdiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by dyspnea and loss of lung function. Transforming growth factor-β (TGF-β) activation mediated by α integrins is central to the pathogenesis of IPF. Bexotegrast (PLN-74809) is an oral, once-daily, dual-selective inhibitor of αβ and αβ integrins under investigation for the treatment of IPF.
View Article and Find Full Text PDFBackground: Imbalance is the most commonly reported side effect following focused ultrasound (FUS) thalamotomy for essential tremor (ET). It remains unknown which patients are more likely to develop imbalance following FUS treatment.
Objective: To identify preoperative and treatment-related sonication parameters that are predictive of imbalance following FUS treatment.